Preparation method for glucosamine chondroitin cream for relieving discomfort of bones, muscles, and ligaments

Abstract

A preparation method for a glucosamine chondroitin cream for relieving discomfort of bones, muscles, and ligaments, relating to the field of topical application. The method comprises: collecting preparation node characteristic indicators of linear preparation nodes and purification liquid and centrifuge tube characteristic indicators of a purification device of each stage of preparation node, and dividing the linear preparation nodes into preceding preparation nodes and subsequent preparation nodes; inputting a purification result of a preceding purification device of a preceding preparation node into a subsequent purification device of a subsequent preparation node as a purification raw material of the subsequent purification device; on the basis of concentration information of the preceding and subsequent purification devices, the preparation node characteristic indicators and the purification liquid and centrifuge tube characteristic indicators, computing purification intermediate waste amounts, natural oxidation raw material amounts, and corresponding glucosamine chondroitin cream increase amounts of the linear preparation nodes; and on this basis, scheduling the purification devices of the linear preparation nodes, so that the purification devices operate in an optimized state. The method can rationally reduce purification intermediate waste.

Description

Preparation method of glucosamine chondroitin cream to relieve bone, muscle and ligament discomfort

[0001] This application claims priority to Chinese Patent Application No. 202411436160.0, filed on October 15, 2024, entitled “Preparation method of glucosamine chondroitin cream for relieving bone, muscle and ligament discomfort”, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This application belongs to the field of topical application, specifically relating to a method for preparing a glucosamine chondroitin cream for relieving discomfort in bones, muscles and ligaments. Background Technology

[0003] Studies have shown that as we age, the functions of all tissues and organs gradually decline, and the depletion of glucosamine exceeds its production. As a result, the body's glucosamine levels are no longer sufficient to meet its own needs, leading to softening and loss of elasticity of the articular cartilage matrix, destruction of collagen fiber connective tissue, and enlargement of cartilage surface cavities, resulting in bone hyperplasia and osteoarthritis.

[0004] However, the existing glucosamine chondroitin cream preparation process lacks effective cost control methods, especially for the multi-stage purification process. The waste and recycling of the products from each purification stage are not very efficient, which makes it impossible to improve the preparation process of glucosamine chondroitin cream. Application content

[0005] To achieve the above objectives, this application provides the following technical solution:

[0006] According to the first aspect of this application, this application claims protection for a method of preparing a glucosamine chondroitin cream for relieving bone, muscle, and ligament discomfort, comprising:

[0007] The characteristic indicators of the preparation nodes of the linear preparation nodes and the characteristic indicators of the purified liquid and centrifuge tubes of the purification equipment at each level of the preparation nodes are collected to classify the linear preparation nodes into pre-preparation nodes and subsequent preparation nodes.

[0008] The purification result of the pre-purification equipment of the pre-preparation node is input into the subsequent purification equipment of the subsequent preparation node as the purification raw material of the subsequent preparation node;

[0009] Based on the concentration information of the pre-purification equipment and the subsequent purification equipment, combined with the characteristic indicators of the preparation node and the characteristic indicators of the purified liquid and centrifuge tube, the amount of intermediate waste, the amount of naturally oxidized raw materials, and the corresponding increase in glucosamine chondroitin cream of the linear preparation node are calculated.

[0010] The purification equipment at the linear preparation node is scheduled according to the amount of intermediate waste, the amount of raw materials from natural oxidation, and the corresponding increase in glucosamine chondroitin cream, so that the purification equipment operates in an optimized state.

[0011] Furthermore, the collection of the characteristic indicators of the linear preparation node and the characteristic indicators of the purified liquid and centrifuge tubes of the purification equipment at each preparation node also includes:

[0012] The fabrication node characteristic indicators of the linear fabrication node include at least the following:

[0013] Preparation cycle, preparation power, total preparation volume, intermediate product arrival time, concentration rate;

[0014] The characteristics of the purified solution and centrifuge tubes include at least the following:

[0015] Type of purification solution, state of purification solution, concentration of purification solution, centrifugation rate of centrifuge tube;

[0016] The purification solution includes at least the following types: calcium chloride purification solution, sodium chloride purification solution, and chondroitin sulfate purification solution;

[0017] The purification solution states include at least: alkaline purification solution, neutral purification solution, weak acid purification solution, and strong acid purification solution.

[0018] Furthermore, the step of dividing the linear fabrication node into a preceding fabrication node and a subsequent fabrication node also includes:

[0019] The linear fabrication node includes at least: a first fabrication node, a second fabrication node, a third fabrication node, and a fourth fabrication node;

[0020] The output of the first preparation node is concentrated into the purified raw material of the second preparation node;

[0021] The output of the second preparation node is concentrated into the purified raw material of the third preparation node;

[0022] The output of the third preparation node is concentrated into the purified raw material of the fourth preparation node;

[0023] The first preparation node is a pre-preparation node preceding the second, third, and fourth preparation nodes;

[0024] The second, third, and fourth preparation nodes are preparation nodes that follow the first preparation node;

[0025] The second preparation node is a pre-preparation node for the third and fourth preparation nodes;

[0026] The third and fourth preparation nodes are preparation nodes that follow the second preparation node;

[0027] The third preparation node is a pre-preparation node of the fourth preparation node;

[0028] The fourth preparation node is a successor preparation node to the third preparation node.

[0029] Furthermore, the purification result of the pre-purification equipment of the pre-preparation node is input into the subsequent purification equipment of the subsequent preparation node as the purification raw material of the subsequent preparation node, and further includes:

[0030] The purification equipment of the first preparation node is an annual purification equipment with the largest centrifuge tube capacity. It adjusts the daily raw material delivery and redistributes the annual raw material delivery. It stores intermediate products from high-order-volume cycles for use in low-order-volume cycles. During low-order-volume cycles, it is in a low-frequency state for subsequent preparation nodes to operate alternately.

[0031] The purification equipment of the second preparation node is a weekly purification equipment. During periods of low order volume, the chondroitin produced is supplied by the chondroitin produced by the purification equipment of the first preparation node. During periods of high order volume, the first preparation node supplies a first proportion of the amount of ecological medicine, and the rest is produced by the natural oxidation of raw materials.

[0032] The centrifuge tube capacity of the purification equipment at the third preparation node is less than a preset capacity threshold. It relies on the amount of intermediate product from the purification equipment at the second preparation node for preparation and is responsible for the production and daily use of medicines.

[0033] The fourth preparation node has the smallest centrifuge tube capacity for purification equipment. During periods of low order volume, it relies on the amount of intermediate products from the purification equipment of the third preparation node for preparation, while during periods of high order volume, it also relies on the amount of environmental byproducts for preparation.

[0034] Furthermore, calculating the amount of purification intermediate waste at the linear preparation node also includes:

[0035] The total amount prepared by the second preparation node under neutral purification solution is collected. Based on the preparation power and concentration rate of the second preparation node, the elution and dialysis volume of the second neutral purification solution prepared by the second preparation node is calculated.

[0036] The total amount prepared by the third preparation node under neutral purification solution is collected. Based on the preparation power and concentration rate of the third preparation node, the elution and dialysis volume of the third neutral purification solution prepared by the third preparation node is calculated.

[0037] Based on the elution and dialysis volume prepared with the second neutral purification solution and the elution and dialysis volume prepared with the third neutral purification solution, the amount of intermediate waste in the neutral purification solution at the linear preparation node is calculated.

[0038] The total amount of preparation at the second preparation node under weak acid purification solution and strong acid purification solution is collected. Based on the preparation power and concentration rate of the second preparation node, the second medium-low preparation elution dialysis volume of the second preparation node is calculated.

[0039] The total amount of preparation at the third preparation node under weak acid purification solution and strong acid purification solution is collected. Based on the preparation power and concentration rate of the third preparation node, the third medium-low preparation elution dialysis volume of the third preparation node is calculated.

[0040] Based on the second low-to-medium preparation elution dialysis volume and the low-to-medium neutral purification solution preparation elution dialysis volume, the amount of intermediate waste in the purification of the linear preparation node in the weak acid purification solution and the strong acid purification solution is calculated.

[0041] Based on the amount of intermediate waste generated during purification in neutral purification solution and in weak acid and strong acid purification solutions at the linear preparation node, and in conjunction with the preparation cycle, the amount of intermediate waste generated during purification at the linear preparation node is calculated.

[0042] Furthermore, calculating the amount of naturally oxidized raw materials for the linear preparation node also includes:

[0043] The difference in centrifugation rate of the first centrifuge tube at the second preparation node is collected when the first and second purification solutions are in a strong acid purification solution;

[0044] Based on the centrifugation rate difference of the first centrifuge tube and combined with the concentration rate of the second preparation node, the first full-load processing time of the second preparation node is calculated.

[0045] Based on the first full-load processing time and the intermediate product arrival and connection time from the first preparation node to the second preparation node, determine whether it affects the full-load processing operation status of the second preparation node, the third preparation node, and the fourth preparation node.

[0046] The difference in centrifugation rate of the second centrifuge tube at the third preparation node when the concentration of the third purification solution and the concentration of the fourth purification solution in the strong acid purification solution are collected;

[0047] Based on the centrifugation rate difference of the second centrifuge tube and combined with the concentration rate of the third preparation node, the second full-load processing time of the third preparation node is calculated.

[0048] Based on the second full-load processing time and the intermediate product arrival and connection time from the second preparation node to the third preparation node, it is determined whether it affects the full-load processing operation status of the third preparation node and the fourth preparation node.

[0049] The difference in centrifugation rate of the third centrifuge tube at the concentrations of the fifth and sixth purification solutions in the strong acid purification solution at the fourth preparation node is collected.

[0050] Based on the centrifugation rate difference of the third centrifuge tube and the concentration rate of the fourth preparation node, the third full-load processing time of the fourth preparation node is calculated.

[0051] Based on the third full-load processing time and the intermediate product arrival and connection time from the third preparation node to the fourth preparation node, it is determined whether it affects the full-load processing operation status of the fourth preparation node.

[0052] Furthermore, calculating the increase in glucosamine chondroitin cream corresponding to the linear preparation node also includes:

[0053] Based on the amount of intermediate waste from purification, the preparation power of the third preparation node, and the concentration rate, the daily increase in preparation volume is calculated.

[0054] The first increase in production volume was calculated based on the peak medical usage period and the daily increase in production volume.

[0055] Based on the environmental product quantity, preparation power, and concentration rate of the linear preparation node, the second preparation quantity increase value is calculated.

[0056] The increase in the first preparation amount is added to the increase in the second preparation amount to obtain the increase in glucosamine chondroitin cream.

[0057] Furthermore, the purification equipment at the linear preparation node is scheduled based on the amount of intermediate purification waste, the amount of naturally oxidized raw materials, and the corresponding increase in glucosamine chondroitin cream, so that the purification equipment operates in an optimized state. This also includes:

[0058] When the amount of intermediate waste from purification, the amount of raw materials from natural oxidation, and the corresponding increase in glucosamine chondroitin cream meet the preset conditions, the purification equipment at the second preparation node maintains the concentration of the first purified solution during low order volume periods to improve resource utilization, maintains the concentration of the second purified solution at or below the environmental level, and naturally oxidizes the raw materials.

[0059] The purification equipment at the third preparation node is adjusted according to the concentration range of the third and fourth purified solutions during peak medical drug use periods, and maintains the fourth purified solution concentration or below during off-peak medical drug use periods to reduce the loss of intermediate purification waste and secondary resource loss.

[0060] The purification equipment at the fourth preparation node maintains the fifth purification solution concentration during periods of low order volume to improve resource utilization, and maintains the sixth purification solution concentration or below to integrate the amount of usable natural products.

[0061] This application pertains to the field of topical application, specifically relating to a method for preparing glucosamine chondroitin cream to relieve discomfort in bones, muscles, and ligaments. It involves collecting characteristic indicators of the linear preparation nodes and the purified solution and centrifuge tube characteristics of the purification equipment at each stage of the preparation process, thus dividing the linear preparation nodes into pre-preparation and subsequent preparation nodes. The purification results from the pre-preparation purification equipment of the pre-preparation nodes are input into the subsequent purification equipment of the subsequent preparation nodes as their purification raw materials. Based on the concentration information from the pre-preparation and subsequent purification equipment, combined with the characteristic indicators of the preparation nodes and the purified solution and centrifuge tube characteristics, the amount of intermediate purification waste, the amount of naturally oxidized raw materials, and the corresponding increase in glucosamine chondroitin cream at the linear preparation nodes are calculated. This method is then used to schedule the purification equipment at the linear preparation nodes, ensuring that the purification equipment operates in an optimized state. This application effectively reduces intermediate purification waste and optimizes the effective integration of environmental products into the purified solution, bringing significant economic benefits to enterprises. Attached Figure Description

[0062] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0063] Figure 1 is a flowchart of the preparation method of the glucosamine chondroitin cream for relieving bone, muscle and ligament discomfort claimed in the embodiments of this application. Detailed Implementation

[0064] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only a part of the embodiments of this application, and not all of the embodiments. Based on the embodiments of this application, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of this application.

[0065] The terms "first," "second," and "third" in this application are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Therefore, a feature defined as "first," "second," or "third" may explicitly or implicitly include at least one of that feature. In the description of this application, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified. All directional indications (such as up, down, left, right, front, back, etc.) in the embodiments of this application are only used to explain the relative positional relationships and movements between components in a specific orientation (as shown in the figures). If the specific orientation changes, the directional indications also change accordingly. Furthermore, the terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or device that includes a series of steps or modules is not limited to the listed steps or modules, but may optionally include steps or modules not listed, or may optionally include other steps or modules inherent to these processes, methods, products, or devices.

[0066] In this document, the term "embodiment" means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The appearance of this phrase in various places throughout the specification does not necessarily refer to the same embodiment, nor is it a mutually exclusive, independent, or alternative embodiment. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.

[0067] According to the first embodiment of this application, referring to FIG1, this application claims a method for preparing glucosamine chondroitin cream for relieving bone, muscle, and ligament discomfort, comprising:

[0068] The characteristic indicators of the preparation nodes of the linear preparation nodes and the characteristic indicators of the purified liquid and centrifuge tubes of the purification equipment at each level of the preparation nodes are collected to classify the linear preparation nodes into pre-preparation nodes and subsequent preparation nodes.

[0069] The purification result of the pre-purification equipment of the pre-preparation node is input into the subsequent purification equipment of the subsequent preparation node as the purification raw material of the subsequent preparation node;

[0070] Based on the concentration information of the pre-purification equipment and the subsequent purification equipment, combined with the characteristic indicators of the preparation node and the characteristic indicators of the purified liquid and centrifuge tube, the amount of intermediate waste, the amount of naturally oxidized raw materials, and the corresponding increase in glucosamine chondroitin cream of the linear preparation node are calculated.

[0071] The purification equipment at the linear preparation node is scheduled according to the amount of intermediate waste, the amount of raw materials from natural oxidation, and the corresponding increase in glucosamine chondroitin cream, so that the purification equipment operates in an optimized state.

[0072] In this embodiment, the ingredients of the glucosamine chondroitin soothing cream include, but are not limited to: glucosamine, chondroitin, sodium hyaluronate, elderberry extract, safflower extract, Panax notoginseng extract, Gastrodia elata extract, olive fruit oil, and rosemary leaf oil.

[0073] Among them, glucosamine and chondroitin: repair and thicken cartilage, and avoid pain caused by friction between hard bones;

[0074] Sodium hyaluronate: Increases synovial fluid, lubricates joints, and allows for free joint movement;

[0075] Elderberry extract: repairs damaged bone and prevents bone fragments from entering surrounding tissues, causing redness, swelling, heat, and pain;

[0076] Safflower extract and Panax notoginseng extract: promote blood circulation, reduce swelling and pain, and help repair ligaments;

[0077] Olive fruit oil and rosemary leaf oil: These have strong penetrating power to open skin pores and act as carriers to carry other nutrients deep into the skin, promoting the penetration of other nutrients into the deeper layers of the skin, and then directly reaching muscles and joints. They accumulate in the affected areas of muscles and joints and exert their effective effects, resulting in more precise and faster absorption and improved penetration and utilization of each ingredient.

[0078] When applied topically, this product can relieve discomfort such as pain, numbness, stiffness, and soreness in joints and muscles. It can also quickly help relieve pain and promote timely repair during sports injuries, preventing further sports injuries. Long-term use can provide comprehensive care for joints, ligaments, and muscles.

[0079] This product is gentle on the skin, free of hormones and irritants, and will not irritate the stomach or intestines, nor affect blood sugar or blood pressure. It is safe for a wide range of people to use.

[0080] The product prepared according to this application adopts a press-type fully enclosed bottle design, which can effectively block the pollution of external air and dust, ensure that the active ingredients do not oxidize or volatilize, and always maintain the best quality and purity of the product.

[0081] The term "naturally oxidized raw material" refers to the raw material that has undergone oxidation due to contact with ambient air and moisture during purification and transportation processes. Naturally oxidized raw materials accelerate the purification process of unoxidized raw materials to a certain extent.

[0082] Furthermore, the collection of the characteristic indicators of the linear preparation node and the characteristic indicators of the purified liquid and centrifuge tubes of the purification equipment at each preparation node also includes:

[0083] The fabrication node characteristic indicators of the linear fabrication node include at least the following:

[0084] Preparation cycle, preparation power, total preparation volume, intermediate product arrival time, concentration rate;

[0085] The characteristics of the purified solution and centrifuge tubes include at least the following:

[0086] Type of purification solution, state of purification solution, concentration of purification solution, centrifugation rate of centrifuge tube;

[0087] The purification solution includes at least the following types: calcium chloride purification solution, sodium chloride purification solution, and chondroitin sulfate purification solution;

[0088] The purification solution states include at least: alkaline purification solution, neutral purification solution, weak acid purification solution, and strong acid purification solution.

[0089] In this embodiment, the pH value of the alkaline purification solution is greater than 7, the pH value of the neutral purification solution is equal to 7, the pH value of the weak acid purification solution is 6.5-7, and the pH value of the strong acid purification solution is less than 6.5.

[0090] Furthermore, the step of dividing the linear fabrication node into a preceding fabrication node and a subsequent fabrication node also includes:

[0091] The linear fabrication node includes at least: a first fabrication node, a second fabrication node, a third fabrication node, and a fourth fabrication node;

[0092] The output of the first preparation node is concentrated into the purified raw material of the second preparation node;

[0093] The output of the second preparation node is concentrated into the purified raw material of the third preparation node;

[0094] The output of the third preparation node is concentrated into the purified raw material of the fourth preparation node;

[0095] The first preparation node is a pre-preparation node preceding the second, third, and fourth preparation nodes;

[0096] The second, third, and fourth preparation nodes are preparation nodes that follow the first preparation node;

[0097] The second preparation node is a pre-preparation node for the third and fourth preparation nodes;

[0098] The third and fourth preparation nodes are preparation nodes that follow the second preparation node;

[0099] The third preparation node is a pre-preparation node of the fourth preparation node;

[0100] The fourth preparation node is a successor preparation node to the third preparation node.

[0101] Furthermore, the purification result of the pre-purification equipment of the pre-preparation node is input into the subsequent purification equipment of the subsequent preparation node as the purification raw material of the subsequent preparation node, and further includes:

[0102] The purification equipment of the first preparation node is an annual purification equipment with the largest centrifuge tube capacity. It adjusts the daily raw material delivery and redistributes the annual raw material delivery. It stores intermediate products from high-order-volume cycles for use in low-order-volume cycles. During low-order-volume cycles, it is in a low-frequency state for subsequent preparation nodes to operate alternately.

[0103] The purification equipment of the second preparation node is a weekly purification equipment. During periods of low order volume, the chondroitin produced is supplied by the chondroitin produced by the purification equipment of the first preparation node. During periods of high order volume, the first preparation node supplies a first proportion of the amount of ecological medicine, and the rest is produced by the natural oxidation of raw materials.

[0104] The centrifuge tube capacity of the purification equipment at the third preparation node is less than a preset capacity threshold. It relies on the amount of intermediate product from the purification equipment at the second preparation node for preparation and is responsible for the production and daily use of medicines.

[0105] The fourth preparation node has the smallest centrifuge tube capacity for purification equipment. During periods of low order volume, it relies on the amount of intermediate products from the purification equipment of the third preparation node for preparation, while during periods of high order volume, it also relies on the amount of environmental byproducts for preparation.

[0106] Furthermore, calculating the amount of purification intermediate waste at the linear preparation node also includes:

[0107] The total amount prepared by the second preparation node under neutral purification solution is collected. Based on the preparation power and concentration rate of the second preparation node, the elution and dialysis volume of the second neutral purification solution prepared by the second preparation node is calculated.

[0108] The total amount prepared by the third preparation node under neutral purification solution is collected. Based on the preparation power and concentration rate of the third preparation node, the elution and dialysis volume of the third neutral purification solution prepared by the third preparation node is calculated.

[0109] Based on the elution and dialysis volume prepared with the second neutral purification solution and the elution and dialysis volume prepared with the third neutral purification solution, the amount of intermediate waste in the neutral purification solution at the linear preparation node is calculated.

[0110] The total amount of preparation at the second preparation node under weak acid purification solution and strong acid purification solution is collected. Based on the preparation power and concentration rate of the second preparation node, the second medium-low preparation elution dialysis volume of the second preparation node is calculated.

[0111] The total amount of preparation at the third preparation node under weak acid purification solution and strong acid purification solution is collected. Based on the preparation power and concentration rate of the third preparation node, the third medium-low preparation elution dialysis volume of the third preparation node is calculated.

[0112] Based on the second low-to-medium preparation elution dialysis volume and the low-to-medium neutral purification solution preparation elution dialysis volume, the amount of intermediate waste in the purification of the linear preparation node in the weak acid purification solution and the strong acid purification solution is calculated.

[0113] Based on the amount of intermediate waste generated during purification in neutral purification solution and in weak acid and strong acid purification solutions at the linear preparation node, and in conjunction with the preparation cycle, the amount of intermediate waste generated during purification at the linear preparation node is calculated.

[0114] Furthermore, calculating the amount of naturally oxidized raw materials for the linear preparation node also includes:

[0115] The difference in centrifugation rate of the first centrifuge tube at the second preparation node is collected when the first and second purification solutions are in a strong acid purification solution;

[0116] Based on the centrifugation rate difference of the first centrifuge tube and combined with the concentration rate of the second preparation node, the first full-load processing time of the second preparation node is calculated.

[0117] Based on the first full-load processing time and the intermediate product arrival and connection time from the first preparation node to the second preparation node, determine whether it affects the full-load processing operation status of the second preparation node, the third preparation node, and the fourth preparation node.

[0118] The difference in centrifugation rate of the second centrifuge tube at the third preparation node when the concentration of the third purification solution and the concentration of the fourth purification solution in the strong acid purification solution are collected;

[0119] Based on the centrifugation rate difference of the second centrifuge tube and combined with the concentration rate of the third preparation node, the second full-load processing time of the third preparation node is calculated.

[0120] Based on the second full-load processing time and the intermediate product arrival and connection time from the second preparation node to the third preparation node, it is determined whether it affects the full-load processing operation status of the third preparation node and the fourth preparation node.

[0121] The difference in centrifugation rate of the third centrifuge tube at the concentrations of the fifth and sixth purification solutions in the strong acid purification solution at the fourth preparation node is collected.

[0122] Based on the centrifugation rate difference of the third centrifuge tube and the concentration rate of the fourth preparation node, the third full-load processing time of the fourth preparation node is calculated.

[0123] Based on the third full-load processing time and the intermediate product arrival and connection time from the third preparation node to the fourth preparation node, it is determined whether it affects the full-load processing operation status of the fourth preparation node.

[0124] Furthermore, calculating the increase in glucosamine chondroitin cream corresponding to the linear preparation node also includes:

[0125] Based on the amount of intermediate waste from purification, the preparation power of the third preparation node, and the concentration rate, the daily increase in preparation volume is calculated.

[0126] The first increase in production volume was calculated based on the peak medical usage period and the daily increase in production volume.

[0127] Based on the environmental product quantity, preparation power, and concentration rate of the linear preparation node, the second preparation quantity increase value is calculated.

[0128] The increase in the first preparation amount is added to the increase in the second preparation amount to obtain the increase in glucosamine chondroitin cream.

[0129] Furthermore, the purification equipment at the linear preparation node is scheduled based on the amount of intermediate purification waste, the amount of naturally oxidized raw materials, and the corresponding increase in glucosamine chondroitin cream, so that the purification equipment operates in an optimized state. This also includes:

[0130] When the amount of intermediate waste from purification, the amount of raw materials from natural oxidation, and the corresponding increase in glucosamine chondroitin cream meet the preset conditions, the purification equipment at the second preparation node maintains the concentration of the first purified solution during low order volume periods to improve resource utilization, maintains the concentration of the second purified solution at or below the environmental level, and naturally oxidizes the raw materials.

[0131] The purification equipment at the third preparation node is adjusted according to the concentration range of the third and fourth purified solutions during peak medical drug use periods, and maintains the fourth purified solution concentration or below during off-peak medical drug use periods to reduce the loss of intermediate purification waste and secondary resource loss.

[0132] The purification equipment at the fourth preparation node maintains the fifth purification solution concentration during periods of low order volume to improve resource utilization, and maintains the sixth purification solution concentration or below to integrate the amount of usable natural products.

[0133] In the several embodiments provided in this application, it should be understood that the disclosed systems, devices, and methods can be implemented in other ways. For example, the device embodiments described above are merely illustrative; for instance, the division of modules is only a logical functional division, and in actual implementation, there may be other division methods. For example, multiple modules or components may be combined or integrated into another system, or some features may be ignored or not executed. Furthermore, the coupling or direct coupling or communication connection shown or discussed may be through some interfaces; the indirect coupling or communication connection between devices or modules may be electrical, mechanical, or other forms.

[0134] Furthermore, the functional modules in the various embodiments of this application can be integrated into one processing module, or each module can exist physically separately, or two or more modules can be integrated into one module. The integrated modules can be implemented in hardware or as software functional modules. The above are merely embodiments of this application and do not limit the patent scope of this application. Any equivalent structural or procedural transformations made using the content of this application's specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the patent protection scope of this application.

[0135] The specific embodiments of the invention have been described in detail above, but they are only examples, and this application is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modifications or substitutions to the invention are also within the scope of this application. Therefore, all equivalent changes, modifications, and improvements made without departing from the spirit and principles of this application should be covered within the scope of this application.

Claims

1. A method for preparing an amino sugar chondroitin cream for relieving bone, muscle and ligament discomfort, characterized by, include: The characteristic indicators of the linear preparation nodes and the characteristic indicators of the purified liquid and centrifuge tubes of the purification equipment at each level of the preparation nodes are collected to classify the linear preparation nodes into pre-preparation nodes and subsequent preparation nodes. The purification result of the pre-purification equipment of the pre-preparation node is input into the subsequent purification equipment of the subsequent preparation node as the purification raw material of the subsequent preparation node; Based on the concentration information of the pre-purification equipment and the subsequent purification equipment, combined with the characteristic indicators of the preparation node and the characteristic indicators of the purified liquid and centrifuge tube, the amount of intermediate waste, the amount of naturally oxidized raw materials, and the corresponding increase in glucosamine chondroitin cream of the linear preparation node are calculated. The purification equipment at the linear preparation node is scheduled according to the amount of intermediate waste, the amount of raw materials from natural oxidation, and the corresponding increase in glucosamine chondroitin cream, so that the purification equipment operates in an optimized state.

2. The method of preparing the chondroitin cream for relieving bone, muscle and ligament discomfort according to claim 1, characterized in that, The method of collecting the characteristic indicators of the linear preparation node and the characteristic indicators of the purified liquid and centrifuge tubes of the purification equipment at each preparation node also includes: The fabrication node characteristic indicators of the linear fabrication node include at least the following: Preparation cycle, preparation power, total preparation volume, intermediate product arrival time, concentration rate; The characteristics of the purified solution and centrifuge tubes include at least the following: Type of purification solution, state of purification solution, concentration of purification solution, centrifugation rate of centrifuge tube; The purification solution includes at least the following types: calcium chloride purification solution, sodium chloride purification solution, and chondroitin sulfate purification solution; The purification solution states include at least: alkaline purification solution, neutral purification solution, weak acid purification solution, and strong acid purification solution.

3. The method of preparing the chondroitin glucosamine cream for relieving bone, muscle and ligament discomfort according to claim 2, characterized in that, The division of the linear fabrication nodes into preceding fabrication nodes and subsequent fabrication nodes further includes: The linear fabrication node includes at least: a first fabrication node, a second fabrication node, a third fabrication node, and a fourth fabrication node; The output of the first preparation node is concentrated into the purified raw material of the second preparation node; The output of the second preparation node is concentrated into the purified raw material of the third preparation node; The output of the third preparation node is concentrated into the purified raw material of the fourth preparation node; The first preparation node is a pre-preparation node preceding the second, third, and fourth preparation nodes; The second, third, and fourth preparation nodes are preparation nodes that follow the first preparation node; The second preparation node is a pre-preparation node for the third and fourth preparation nodes; The third and fourth preparation nodes are preparation nodes that follow the second preparation node; The third preparation node is a pre-preparation node of the fourth preparation node; The fourth preparation node is a successor preparation node to the third preparation node.

4. The method for preparing the glucosamine chondroitin cream for relieving bone, muscle, and ligament discomfort according to claim 3, characterized in that, The purification result of the pre-purification device at the pre-preparation node is input into the subsequent purification device at the subsequent preparation node as the purification raw material for the subsequent preparation node, and further includes: The purification equipment of the first preparation node is an annual purification equipment with the largest centrifuge tube capacity. It adjusts the daily raw material delivery and redistributes the annual raw material delivery. It stores intermediate products from high-order-volume cycles for use in low-order-volume cycles. During low-order-volume cycles, it is in a low-frequency state for subsequent preparation nodes to operate alternately. The purification equipment of the second preparation node is a weekly purification equipment. During periods of low order volume, the chondroitin produced is supplied by the chondroitin produced by the purification equipment of the first preparation node. During periods of high order volume, the first preparation node supplies a first proportion of the amount of ecological medicine, and the rest is produced by the natural oxidation of raw materials. The centrifuge tube capacity of the purification equipment at the third preparation node is less than a preset capacity threshold. It relies on the amount of intermediate product from the purification equipment at the second preparation node for preparation and is responsible for the production and daily use of medicines. The fourth preparation node has the smallest centrifuge tube capacity for purification equipment. During periods of low order volume, it relies on the amount of intermediate products from the purification equipment of the third preparation node for preparation, while during periods of high order volume, it also relies on the amount of environmental byproducts for preparation.

5. The method of claim 4, wherein the preparation of the chondroitin cream for relieving bone, muscle and ligament discomfort is characterized by, The calculation of the amount of purification intermediate waste from the linear preparation node also includes: The total amount prepared by the second preparation node under neutral purification solution is collected. Based on the preparation power and concentration rate of the second preparation node, the elution and dialysis volume of the second neutral purification solution prepared by the second preparation node is calculated. The total amount prepared by the third preparation node under neutral purification solution is collected. Based on the preparation power and concentration rate of the third preparation node, the elution and dialysis volume of the third neutral purification solution prepared by the third preparation node is calculated. Based on the elution and dialysis volume prepared with the second neutral purification solution and the elution and dialysis volume prepared with the third neutral purification solution, the amount of intermediate waste in the neutral purification solution at the linear preparation node is calculated. The total amount of preparation at the second preparation node under weak acid purification solution and strong acid purification solution is collected. Based on the preparation power and concentration rate of the second preparation node, the second medium-low preparation elution dialysis volume of the second preparation node is calculated. The total amount of preparation at the third preparation node under weak acid purification solution and strong acid purification solution is collected. Based on the preparation power and concentration rate of the third preparation node, the third medium-low preparation elution dialysis volume of the third preparation node is calculated. Based on the second low-to-medium preparation elution dialysis volume and the low-to-medium neutral purification solution preparation elution dialysis volume, the amount of intermediate waste in the purification of the linear preparation node in the weak acid purification solution and the strong acid purification solution is calculated. Based on the amount of intermediate waste generated during purification in neutral purification solution and in weak acid and strong acid purification solutions at the linear preparation node, and in conjunction with the preparation cycle, the amount of intermediate waste generated during purification at the linear preparation node is calculated.

6. The method of claim 5, wherein the preparation of the chondroitin cream for relieving bone, muscle and ligament discomfort is characterized by, The calculation of the amount of naturally oxidized raw materials for the linear preparation node also includes: The difference in centrifugation rate of the first centrifuge tube at the second preparation node is collected when the first and second purification solutions are in a strong acid purification solution; Based on the centrifugation rate difference of the first centrifuge tube and combined with the concentration rate of the second preparation node, the first full-load processing time of the second preparation node is calculated. Based on the first full-load processing time and the intermediate product arrival and connection time from the first preparation node to the second preparation node, determine whether it affects the full-load processing operation status of the second preparation node, the third preparation node, and the fourth preparation node. The difference in centrifugation rate of the second centrifuge tube at the third preparation node when the concentration of the third purification solution and the concentration of the fourth purification solution in the strong acid purification solution are collected; Based on the centrifugation rate difference of the second centrifuge tube and combined with the concentration rate of the third preparation node, the second full-load processing time of the third preparation node is calculated. Based on the second full-load processing time and the intermediate product arrival and connection time from the second preparation node to the third preparation node, it is determined whether it affects the full-load processing operation status of the third preparation node and the fourth preparation node. The difference in centrifugation rate of the third centrifuge tube at the concentrations of the fifth and sixth purification solutions in the strong acid purification solution at the fourth preparation node is collected. Based on the centrifugation rate difference of the third centrifuge tube and the concentration rate of the fourth preparation node, the third full-load processing time of the fourth preparation node is calculated. Based on the third full-load processing time and the intermediate product arrival and connection time from the third preparation node to the fourth preparation node, it is determined whether it affects the full-load processing operation status of the fourth preparation node.

7. The method of claim 6, wherein the preparation of the chondroitin cream for relieving bone, muscle and ligament discomfort is characterized by, The calculation of the increase in glucosamine chondroitin cream corresponding to the linear preparation node also includes: Based on the amount of intermediate waste from purification, the preparation power of the third preparation node, and the concentration rate, the daily increase in preparation volume is calculated. The first increase in production volume was calculated based on the peak medical usage period and the daily increase in production volume. Based on the environmental product quantity, preparation power, and concentration rate of the linear preparation node, the second preparation quantity increase value is calculated. The increase in the first preparation amount is added to the increase in the second preparation amount to obtain the increase in glucosamine chondroitin cream.

8. The method of claim 7, wherein the glucosamine chondroitin cream for relieving bone, muscle and ligament discomfort is prepared by the steps of: Based on the amount of intermediate purification waste, the amount of naturally oxidized raw materials, and the corresponding increase in glucosamine chondroitin cream, the purification equipment at the linear preparation node is scheduled to operate in an optimized state, further comprising: When the amount of intermediate waste from purification, the amount of raw materials from natural oxidation, and the corresponding increase in glucosamine chondroitin cream meet the preset conditions, the purification equipment at the second preparation node maintains the concentration of the first purified solution during low order volume periods. The purification equipment at the third preparation node is adjusted according to the concentration range of the third and fourth purified solutions during peak medical drug use periods, and maintains the fourth purified solution concentration or below during off-peak medical drug use periods to reduce the loss of intermediate purification waste and secondary resource loss. The purification equipment at the fourth preparation node maintains the fifth purification solution concentration during periods of low order volume.

Images